Demand for weight-loss drugs fuels global rise in counterfeits
[1/2]Boxes of Ozempic, an injectable semaglutide drug used to treat type 2 diabetes manufactured by Novo Nordisk, are seen at a Rock Canyon pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File photo acquire licensing rights Oct 20 (Reuters) – Extraordinary demand for Novo Nordisks (NOVOb.CO) Ozempic and other drugs used for weight loss …